Approaches for recombinant human factor IX production in serum-free suspension cultures.
Ribeirão Preto, Brazil. In Biotechnol Lett, Dec 2015
OBJECTIVE: To establish a serum-free suspension process for production of recombinant human factor IX (rhFIX) based on the human cell line HEK 293T by evaluating two approaches: (1) serum-free suspension adaptation of previously genetic modified cells (293T-FIX); and (2) genetic modification of cells already adapted to such conditions (293T/SF-FIX).
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
London, United Kingdom. In N Engl J Med, 2012
METHODS: We infused a single dose of a serotype-8-pseudotyped, self-complementary adenovirus-associated virus (AAV) vector expressing a codon-optimized human factor IX (FIX) transgene (scAAV2/8-LP1-hFIXco) in a peripheral vein in six patients with severe hemophilia B (FIX activity, <1% of normal values).
Genotype analysis identifies the cause of the "royal disease".
Worcester, United States. In Science, 2009
The mutation occurs in F9, a gene on the X chromosome that encodes blood coagulation factor IX, and is predicted to alter RNA splicing and to lead to production of a truncated form of factor IX. Thus, the royal disease is the severe form of hemophilia, also known as hemophilia B or Christmas disease.